Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

Nature Biotechnology

Volumn 24, Issue 6, 2006, Pages 687-696

  Montini, Eugenio ^a   Cesana, Daniela ^a,b   Schmidt, Manfred ^c,d   Sanvito, Francesca ^e   Ponzoni, Maurilio ^e   Bartholomae, Cynthia ^d   Sergi, Lucia Sergi ^a   Benedicenti, Fabrizio ^a   Ambrosi, Alessandro ^b   Di Serio, Clelia ^b   Doglioni, Claudio ^b,e   Von Kalle, Christof ^c,d,f   Naldini, Luigi ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF FREIBURG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; GENE TRANSFER; MUTAGENESIS; TUMORS;

GENE THERAPY; GENOTOXICITY; PROTOTYPICAL LENTIVIRAL VECTORS; TUMORIGENESIS;

CELL CULTURE;

LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; GENE INSERTION; GENE THERAPY; GENE TRANSFER; GENOTOXICITY; HEMATOPOIETIC STEM CELL; MOUSE; MUTAGENESIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; LENTIVIRUS; MICE; MUTAGENICITY TESTS; NEOPLASMS; TRANSFECTION; VIRUS INTEGRATION;

EID: 33745108790     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1216     Document Type: Article

References (49)

1. Schroder, A. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002).
2. Wu, X., Li, Y., Crise, B. & Burgess, S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751 (2003).
3. Mitchell, R.S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234 (2004).
4. Hematti, P. et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2, e423 (2004).
5. De Palma, M. et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105, 2307-2315 (2005).
6. Nakai, H. et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34, 297-302 (2003).
7. + cells in ADA-deficient SCID neonates. Nat. Med. 4, 775-780 (1998).
8. Malech, H.L. et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 94, 12133-12138 (1997).
9. Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413 (2002).
10. Cavazzana-Calvo, M., Lagresle, C., Hacein-Bey-Abina, S. & Fischer, A. Gene therapy for severe combined immunodeficiency. Annu. Rev. Med. 56, 585-602 (2005).
11. Gaspar, H.B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187 (2004).
12. Bordignon, C. & Roncarolo, M.G. Therapeutic applications for hematopoietic stem cell gene transfer. Nat. Immunol. 3, 318-321 (2002).
13. Hacein-Bey-Abina, S. et al. LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
14. Coffin, J., Hughes, S.H. & Varmus, H.E. Retroviruses (Cold Spring Harbor Laboratory Press, Plainview, 2000).
15. Lund, A.H. et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 32, 160-165 (2002).
16. Suzuki, T. et al. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 32, 166-174 (2002).
17. Mikkers, H. et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat. Genet. 32, 153-159 (2002).
18. Mikkers, H. & Berns, A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv. Cancer Res. 88, 53-99 (2003).
19. Akagi, K., Suzuki, T., Stephens, R.M., Jenkins, N.A. & Copeland, N.G. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 32 Database issue, D523-527 (2004).
20. Dupuy, A.J., Akagi, K., Largaespada, D.A., Copeland, N.G. & Jenkins, N.A. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436, 221-226 (2005).
21. Du, Y., Spence, S.E., Jenkins, N.A. & Copeland, N.G. Cooperating cancer gene identification via oncogenic retrovirus-induced insertional mutagenesis. Blood 106, 2498-2505 (2005).
22. Collier, L.S., Carlson, C.M., Ravimohan, S., Dupuy, A.J. & Largaespada, D.A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436, 272-276 (2005).
23. Wu, X., Luke, B.T. & Burgess, S.M. Redefining the common insertion site. Virology 344, 292-295 (2006).
24. Baum, C. et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 9, 5-13 (2004).
25. Modlich, U. et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105, 4235-4246 (2005).
26. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267 (1996).
27. Kay, M.A., Glorioso, J.C. & Naldini, L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33-40 (2001).
28. Verma, I.M. & Weitzman, M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74, 711-738 (2005).
29. Pawliuk, R. et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294, 2368-2371 (2001).
30. May, C., Rivella, S., Chadburn, A. & Sadelain, M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 99, 1902-1908 (2002).
31. Imren, S. et al. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest. 114, 953-962 (2004).
32. Biffi, A. et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 113, 1118-1129 (2004).
33. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
34. Sherr, C.J. Principles of tumor suppression. Cell 116, 235-246 (2004).
35. Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M. & Naldini, L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25, 217-222 (2000).
36. Roberts, M.R. et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J. Immunol. 161, 375-384 (1998).
37. Schmidt, M. et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 100, 2737-2743 (2002).
38. Ailles, L. et al. Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol. Ther. 6, 615-626 (2002).
39. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
40. Hosack, D.A., Dennis, G., Jr., Sherman, B.T., Lane, H.C. & Lempicki, R.A. Identifying biological themes within lists of genes with EASE. Genome Biol. 4, R70 (2003).
41. Klug, C.A., Cheshier, S. & Weissman, I.L. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 96, 894-901 (2000).
42. Zentilin, L. et al. Variegation of retroviral vector gene expression in myeloid cells. Gene Ther. 7, 153-166 (2000).
43. Hwang, H.C. et al. Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc. Natl. Acad. Sci. USA 99, 11293-11298 (2002).
44. Johnson, C., Lobelle-Rich, P.A., Puetter, A. & Levy, L.S. Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites. J. Virol. 79, 57-66 (2005).
45. Nielsen, A.A., Sorensen, A.B., Schmidt, J. & Pedersen, F.S. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair. J. Virol. 79, 67-78 (2005).
46. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
47. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
48. Hadjantonakis, A.K., Gertsenstein, M., Ikawa, M., Okabe, M. & Nagy, A. Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech. Dev. 76, 79-90 (1998).
49. Ott, M.G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409 (2006).